PDGFR
Platelet-derived growth factor receptor
PDGFR (Platelet-derived growth factor receptors) are cell surface tyrosine kinase receptors for members of the platelet-derived growth factor (PDGF) family. PDGF subunits -A and -B are important factors regulating cell proliferation, cellular differentiation, cell growth, development and many diseases including cancer. There are two forms of the PDGFR: PDGFR alpha and PDGFR beta.
PDGFR Isoform Specific Products
All Product Categories
-
PDGFR Inhibitors
(276)
View all products
-
PDGFR Antagonist
(1)
View all products
-
PDGFR Activators
(3)
View all products
-
PDGFR Modulators
(2)
View all products
-
PDGFR Chemical
(1)
View all products
-
PDGFR Degrader
(1)
View all products
-
PDGFR Control
(1)
View all products
-
PDGFR Ligands
(4)
View all products
-
PDGF-R-alpha Proteins
(12)
View all products
-
PDGF-R-beta Proteins
(8)
View all products
-
PDGFR Proteins
(22)
View all products
-
PDGFR Related Products (320)
Related Products (320)
-
Recombinant Proteins (22)
-
Antibodies (5)
-
PDGFR Isoform Comparison
-
Imatinib-d3 hydrochloride
0 ImagesCat. No.: HY-15463S2CAS No.: 1134803-18-1Synonyms: STI571-d3 hydrochloride; CGP-57148B-d3 hydrochlorideImatinib-d3 (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.
-
E8431
0 ImagesCat. No.: HY-180801CAS No.: 2419580-01-9E8431 is a DCSTAMP antagonist with an IC50 value of 775.8 nM for osteoclastogenesis. E8431 selectively binds to the endoplasmic reticulum domain of DCSTAMP, disrupts its interaction with RAP1B, and inhibits downstream cytoskeleton rearrangement mediated by the RAP1-RAC1 signaling pathway, thereby impeding osteoclast precursor fusion, suppressing bone resorption, and stimulating PDGFBB secretion to promote osteogenesis and angiogenesis. E8431 can be used in the research of osteoporosis.
-
Imatinib Mesylate (Standard)
0 ImagesSynonyms: STI571 Mesylate (Standard); CGP-57148B Mesylate (Standard)Imatinib (Mesylate) (Standard) is the analytical standard of Imatinib (Mesylate). This product is intended for research and analytical applications. Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
-
Pazopanib-d6
0 ImagesSynonyms: GW786034-d6
-
Sunitinib-d10
0 ImagesSynonyms: SU 11248-d10Sunitinib-d10 (SU 11248-d10) is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
-
Ponatinib-d8
0 ImagesSynonyms: AP24534-d8
-
Vasigrobart
0 ImagesCat. No.: HY-P991724CAS No.: 3030730-59-4Synonyms: REGN-13335
-
Sunitinib Malate (Standard)
0 ImagesCat. No.: HY-10255RCAS No.: 341031-54-7Synonyms: SU 11248 Malate (Standard)Sunitinib (Malate) (Standard) is the analytical standard of Sunitinib (Malate). This product is intended for research and analytical applications. Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib Malate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
-
Nintedanib (Standard)
0 ImagesSynonyms: BIBF 1120 (Standard)Nintedanib (Standard) is the analytical standard of Nintedanib. This product is intended for research and analytical applications. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
-
E4177
0 ImagesSynonyms: 57G709E4177 (57G709) is an orally active angiotensin II receptor antagonist. E4177 can inhibit the growth of vascular smooth muscle cells (HASMC) and the increase of cell surface area. In addition, E4177 can also increase the expression of platelet-derived growth factor (PDGF) receptor. E4177 can be used in the study of vascular diseases.
-
Sunitinib (Standard)
0 ImagesCat. No.: HY-10255ARCAS No.: 557795-19-4Synonyms: SU 11248 (Standard)Sunitinib (Standard) is the analytical standard of Sunitinib. This product is intended for research and analytical applications. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
-
PDGFRB Human Pre-designed siRNA Set A
0 ImagesCat. No.: HY-RS10257PDGFRB Human Pre-designed siRNA Set A contains three designed siRNAs for PDGFRB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
-
SU-4313
0 ImagesSU-4313 is a potent protein tyrosine kinases (PTKs) modulator with IC50s of 14.5 μM, 18.8 μM, 11 μM, 16.9 μM, 8.0 μM for PDGFR, FLK-1, EGFR, HER2 Kinase and IGF-1R, respectively. SU-4313 has the potential for modulating tyrosine kinase signal transduction in order to regulate abnormal cell proliferation.
-
Axitinib (Standard)
0 ImagesSynonyms: AG-013736 (Standard)Axitinib (Standard) is the analytical standard of Axitinib. This product is intended for research and analytical applications. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.
-
Crenolanib (Standard)
0 ImagesSynonyms: CP-868596 (Standard)Crenolanib (Standard) is the analytical standard of Crenolanib. This product is intended for research and analytical applications. Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively.
